Eric Zhang serves as Independent Director of the Company. Mr. Zhang is the Managing Partner of New Era Technologies Management Ltd., a company he founded in 2016, which is a multi-strategy investor in biotechnology and applied physical sciences companies. From 2013 until 2016, when he founded New Era Technologies Management Ltd, Mr. Zhang was the manager of his family office investments. Mr. Zhang joined J.P. Morgan’s China Investment Banking team in Hong Kong in 2006. In the subsequent seven years, Mr. Zhang worked for Macquarie Capital and Barclays Capital in Hong Kong, responsible for covering clients in the healthcare and technology sectors in the Greater China region. Mr. Zhang received a Bachelor of Commerce and BA in Economics from Queen’s University in Kingston, Canada.
As the Independent Director of Aravive Inc, the total compensation of Eric Zhang at Aravive Inc is $118,429. There are 6 executives at Aravive Inc getting paid more, with Gail McIntyre having the highest compensation of $713,495.
Eric Zhang is 39, he's been the Independent Director of Aravive Inc since 2018. There are 10 older and no younger executives at Aravive Inc. The oldest executive at Aravive Inc is Fredric Eshelman, 72, who is the Independent Chairman of the Board.
Eric's mailing address filed with the SEC is C/O ARAVIVE, INC., RIVER OAKS TOWER,, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Over the last 6 years, insiders at Aravive Inc have traded over $107,045 worth of Aravive Inc stock and bought 151,333 units worth $1,102,898 . The most active insiders traders include Srinivas Akkaraju, Fredric N Eshelman Ventures... et Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of $11,962. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth $181,818.
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
Aravive Inc executives and other stock owners filed with the SEC include: